Theravance Biopharma, Inc.

NASDAQ:TBPH

Biotechnology

Healthcare
$17.03 -0.42%

-$0.07 today

Market cap
$882.64M
Beta
0.18
P/E (TTM)
7.4
EPS (TTM)
$2.23
52W Low $10.44High $21.03

Volume 10.02M

Average 0.43M

TBPH Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Theravance Biopharma, Inc.NASDAQ: TBPH

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin widens to -46.9%

Operating margin was -46.9% in Q1 FY2026, up 46.9 pp from a year earlier. On a trailing-twelve-month basis it was 0.1%, up 77.0 pp year over year. Over 3 fiscal years it widened by 166.8 pp.

Context

  • Operating margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether next quarter's operating margin reaches the consensus estimate of 23.3%, a +33.7 pp change from the same quarter last year.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-46.9%-85.2 pp QoQ
Last fiscal yearDec 2025
-12.3%+60.6 pp YoY
LTMMar 2026
0.1%+77.0 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+46.9 pp+33.7 pp-13.2 pp
1 year+60.6 pp——
3 years+166.8 pp+76.0 pp-90.7 pp
5 years+118.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-12.3%
Year-over-year change
+60.6pp

Operating Margin vs competitors

How TBPH compares with its peers on the latest reported figures

  • TBPH's LTM Mar 2026 operating margin of 0.1% is the highest of the 6 companies compared; the peer median is -345.2%.
  • Its year-over-year change of +77.0 pp is the 3rd highest of 5, against a peer median of +32.8 pp.
  • Over three fiscal years its change of +166.8 pp compares with a peer median of -211.5 pp.
TBPH Competitors Peer median
Operating Margin for TBPH and competitors
Company Period LTM level YoY 3-year change
TBPHTheravance Biopharma, Inc.LTM Mar 20260.1% +77.0 pp+166.8 pp
GERNGeron CorporationLTM Mar 2026-19.1% +96.4 pp+23217.4 pp
VALNValneva SELTM Mar 2026-63.6% -30.9 pp-15.3 pp
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026-345.2% -343.9 pp—
LENZLENZ Therapeutics, Inc.LTM Mar 2026-563.8% —-407.6 pp
VIRVir Biotechnology, Inc.LTM Mar 2026-704.9% +2394.8 pp-734.2 pp
AVBPArriVent BioPharma, Inc. Common StockFY2025— ——
TYRATyra Biosciences, Inc.FY2025— ——
REPLReplimune Group, Inc.FY2025— ——
Peer median (excluding TBPH) -345.2%+32.8 pp-211.5 pp

Competitors are the stored peer set for TBPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.31M51.35M57.42M64.38M107.46M
Cost of Revenue193.66M63.39M40.62M37.64M5.52M
Gross Profit(138.35M)(12.05M)16.8M26.74M101.95M
Gross Margin-250.1%-23.5%29.3%41.5%94.9%
Research & Development201.55M70.07M46.34M38.05M37.41M
Selling, General & Admin99.3M67.07M70.45M69.17M73.65M
Operating Expenses119.44M79.91M72.84M73.69M115.2M
Depreciation & Amortization4.81M3.04M2M3.62M5.52M
EBITDA(232.83M)(76.08M)(51.65M)(38.45M)137.22M
EBITDA Margin-420.9%-148.2%-89.9%-59.7%127.7%
Operating Income(257.78M)(91.96M)(56.04M)(46.95M)(13.25M)
Operating Margin-466.1%-179.1%-97.6%-72.9%-12.3%
Interest Income1.11M8.55M9.12M4.88M0
Interest Expense8.55M6.37M2.35M2.55M2.46M
Other Income / Expenses(7.44M)(858K)6.77M2.34M142.49M
Income Before Tax(265.22M)(92.82M)(49.27M)(44.61M)129.25M
Pre-Tax Margin-479.5%-180.8%-85.8%-69.3%120.3%
Income Tax Expense(151K)9K5.92M11.8M23.35M
Net Income(199.43M)872.13M(55.19M)(56.42M)105.9M
Net Margin-360.6%1698.5%-96.1%-87.6%98.5%
EPS (Basic)(2.87)(1.26)(1.00)(1.15)2.10
EPS (Diluted)(2.87)(1.26)(1.00)(1.15)2.06
Weighted Avg Shares69.46M73.59M55.3M48.85M50.32M
Weighted Avg Shares (Diluted)69.46M73.59M55.3M48.85M51.51M

Theravance Biopharma, Inc.

NASDAQ:TBPH

Intrinsic Alpha fair value

Locked

Current Price

$17.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.